DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

  • RESET FILTERS

    Renal Anemia: Disease Landscape & Forecast

    The renal anemia market will expand over our 2016-2026 study period, fueled by increasing prevalence and a high unmet need for drugs that can effectively, safely, and conveniently control the disease. A series of hypoxia inducible factor prolyl hydroxylase (HIF PH) inhibitors are expected to launch over the study period, which will promote market growth. However, these novel therapies will have to demonstrate safety and efficacy benefits over current therapies in order to succeed. Among the HIF PH inhibitors, the most advanced agent is FibroGen/AstraZeneca/Astellas’ roxadustat, which is the subject of several long term Phase III trials. Although these new therapies are expected to demonstrate advantages over current therapies, they will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment.

     

    This report provides answers to the following questions:

    • What opportunities exist for the marketers of the emerging oral HIF PH inhibitors to promote their noninvasive route of administration, particularly for patients not on dialysis?
    • Will establishing cardiovascular (CV) safety be key for the market uptake of HIF PH inhibitors, due to the CV issues associated with current therapies?
    • With the imminent availability of biosimilars in the United States, will emerging therapies offering only incremental improvements over existing therapies struggle?
    • What do key opinion leaders think about the iron based phosphate binder Auryxia for the treatment of renal anemia?

     

    Disease Landscape & Forecast Solution

    This report provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. Learn more about how you can quickly identify, analyze, and act on emerging challenges with timely and accurate insights DRG’s Insights Platform.